BioNTech

高盛看好BioNTech转型前景，上调评级至“买入”

kashif hafeez - February 1, 2026

Goldman Sachs Upgrades BioNTech, Citing Strategic Pivot to Oncology

kashif hafeez - February 1, 2026

BioNTech Shares: Consolidation Phase Precedes Potential Breakout

January 30, 2026

BioNTech战略转型迈出关键一步：高管任命与研发管线双线推进

January 30, 2026

高盛转向看多，BioNTech肿瘤战略迎来关键节点

Brett Shapiro - January 22, 2026

生物科技转型之路：押注肿瘤疗法能否开启新篇章？

kashif hafeez - January 20, 2026

生物新技术公司转型关键期：肿瘤管线能否接棒新冠疫苗收入？

Brett Shapiro - January 19, 2026

BioNTech战略转型获市场青睐，分析师上调预期至2026年

Brett Shapiro - January 18, 2026

生物技术巨头BioNTech转型加速：肿瘤管线成2026年核心引擎

angelina - January 15, 2026

BioNTech战略转型：千亿现金储备驱动肿瘤学新蓝图

kashif hafeez - January 14, 2026

2026年：BioNTech转型之路的关键考验

January 13, 2026

BioNTech战略转型：肿瘤管线布局成为市场新焦点

angelina - January 12, 2026

BioNTech战略转型：肿瘤疗法成为核心增长引擎

angelina - January 10, 2026

BioNTech股价遭遇技术性阻力

Brett Shapiro - January 9, 2026

德国mRNA双雄合体：BioNTech正式完成对CureVac的收购

angelina - January 7, 2026

12 3 4 Page 1 of 4